Short answer
ImmunityBio, Inc. (IBRX) filed an 8-K current report with the SEC on April 6, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). IBRX submitted a comprehensive response to an FDA Office of Prescription Drug Promotion Warning Letter dated March 13, 2026.
ImmunityBio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- IBRX submitted a comprehensive response to an FDA Office of Prescription Drug Promotion Warning Letter dated March 13, 2026
- Corrective actions include immediate and planned measures addressing FDA promotional-compliance concerns
- Regulatory response may affect commercialization activities and investor assessment of FDA execution risk
Item EX-99.1 · Exhibit EX-99.1
- FDA OPDP correspondence concerned an ANKTIVA podcast and television advertisement, creating regulatory and promotional-compliance risk
- Company confirmed the television advertisement was never broadcast or publicly disseminated
- Podcast removed from ImmunityBio’s website, with third-party platform removal requests underway
- Enhanced controls include executive training, expanded Promotional Review Committee protocols, and external regulatory counsel audits
- Clarifications distinguish investigational IL-15 applications and aspirational pipeline claims from ANKTIVA’s approved indication
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ImmunityBio, Inc. 8-K filings
Get the next IBRX 8-K as it lands
Follow IBRX for push alerts, or ask the research agent what this filing means.